BriaCell Therapeutics Corp.

TSX:BCT.TO

Biotechnology

Healthcare
$5.75 +18.88%

+$0.94 today

Market cap
$50.02M
Beta
1.53
P/E (TTM)
-0.3
EPS (TTM)
-$4.23
52W Low $3.68High $20.40

Volume 0.00M

Average 0.01M

BCT.TO Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

BriaCell Therapeutics Corp.TSX: BCT.TO

Depreciation & Amortization · Q3 FY2026 · quarter ended Apr 2026

Depreciation & amortization growth accelerates

Q3 FY2026 depreciation & amortization of $33.01K rose 23.8% year over year, ahead of the -25.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 23.8% from the prior quarter. Over 3 fiscal years it compounded at +91.9% a year.

Context

  • Depreciation & amortization increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +23.8% holds above the trailing-twelve-month pace of -25.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterApr 2026
$33.01K+23.8% QoQ
Last fiscal yearJul 2025
$107.93K+28.6% YoY
LTMApr 2026
$112.91K-25.5% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+23.8%——
1 year+28.6%——
3-year CAGR+91.9%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
107.93K USD
Year-over-year change
+28.6%
4-year CAGR
+63.1%

Depreciation & Amortization vs competitors

How BCT.TO compares with its peers on the latest reported figures

No competitor Depreciation & Amortization figures are available to compare.

Cash Flow Statement

USD
Metric
FY2021
Jul 2021
FY2022
Jul 2022
FY2023
Jul 2023
FY2024
Jul 2024
FY2025
Jul 2025
Net Income(13.82M)(26.84M)(20.3M)(4.93M)(26.63M)
Depreciation & Amortization15.26K15.27K15.27K83.9K107.93K
Deferred Income Tax00000
Stock-Based Compensation1.97M3.07M2.19M1.8M0
Change in Working Capital(2.28M)(391.29K)(3.53M)7.05M(1.93M)
Accounts Receivables9.94K(11.53K)5.23K(732.58K)742.6K
Inventory00000
Accounts Payables(1.41M)249.16K660.46K6.05M(3.93M)
Other Working Capital(886.38K)(628.93K)(4.2M)1.74M1.26M
Other Non-Cash Items6.36M11.66M(2.12M)(28.14M)(58.73K)
Operating Cash Flow(7.75M)(12.48M)(23.74M)(24.13M)(28.51M)
Capital Expenditures000(456.8K)0
Acquisitions (Net)000(225K)0
Purchases of Investments0000(7.74M)
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow000(681.8K)(7.74M)
Debt Repayment(330.4K)0000
Common Stock Issued51.62M04M4.42M46M
Common Stock Repurchased0(10.17M)(47.29K)00
Dividends Paid00000
Other Financing Activities13.71M6.43M1.59K00
Financing Cash Flow65M(3.74M)3.95M4.42M46M
Effect of Forex Changes0000(84.08K)
Net Change in Cash57.25M(16.23M)(19.79M)(20.39M)9.67M
Free Cash Flow(7.75M)(12.48M)(23.74M)(24.58M)(28.51M)

BriaCell Therapeutics Corp.

TSX:BCT.TO

Intrinsic Alpha fair value

Locked

Current Price

$5.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.